CD22 CAR-T Therapy Shows Results in Leukemia, Study Shows, But Could a Dual CAR-T Deliver the One-Two Punch to Avoid Relapse?
The Parker Institute for Cancer Immunotherapy enables real collaboration, accelerating ambitious research to deliver new immunotherapies engineered to save lives.
World-renowned experts from leading cancer centers are at the forefront of our research.
Open in Twitter Parker Institute @parkerici RT @DrMvandenBrink: https://t.co/z1qL0Fsowx 18 hours ago
Open in Twitter Parker Institute @parkerici .@ReadersDigest covers 10 #cancerresearch milestones in 2017. Congrats to PICI scientists and institutions mentione… https://t.co/TWrVUQm7ns 20 hours ago